AzTrials
AzTrials

Female Sexual Arousal DisorderPhase 2RESPONDNCT04948151

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

A Phase 2 study testing Sildenafil in people with Female Sexual Arousal Disorder, run by Strategic Science & Technologies, LLC at 51 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue. Read more about this study

Who is it for?
Ages 21 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Female Sexual Arousal Disorder
What is being tested?
Sildenafil
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
440 participants
Where
51 sitesUnited States
Study dates
28 Jun 2021to 15 Dec 2021
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patient must be a premenopausal woman, 21 years or older.
  • Transgender individuals assigned a female gender at birth will be permitted to enroll provided they are not currently undergoing hormone treatment, have not undergone gender reassignment surgery and do not intend to for the duration of the study.
  • Patient is fluent in the English language.
  • Patient is capable of understanding and complying with the protocol and agrees to sign the informed consent document.
  • Patient has been in a stable, monogamous, relationship that was secure and communicative, for at least 6 months prior to Visit 1. The relationship is with one sexual partner, who is sexually functional, both psychologically and physically. The partner will be consistent and available throughout the duration of the study.
  • Based on the clinical interview, in their past, patient had experienced 'normal' sexual function for at least 2 years or longer. Patient has had sexual activity at least two times each month during the last 6 months and agrees to have sexual activity at least two times each month for the duration of the study). Sexual activity can include any activity which may result in sexual stimulation or sexual pleasure e.g., intercourse, caressing, foreplay, masturbation, and oral sex.
Show all 23Show fewer
  • Patients who have experienced a recent major life stress (e.g., loss of income, death of a family member) or relationship discord that could interfere with sexual activity (except distress related to FSAD) will be excluded.
  • Women of childbearing potential must agree to continue using an acceptable form of birth control during the study and agree to continue to stay on their dose of birth control throughout the duration of the study. Birth control is not required for confirmed same sex couples, couples with confirmed vasectomy or couples with confirmed tubal ligation.
  • Acceptable forms of birth control include the following: intrauterine system [IUS], progestin and/or estrogen-containing hormonal oral contraceptives, contraceptive patch, contraceptive implant, contraceptive injection, or the copper-containing intrauterine device (IUD). Patients must be using the progestin and or estrogen-containing hormonal oral contraceptives or contraceptive patch for least 6 months prior to Visit 1 without clinically significant complications in the opinion of the Investigator. Patients must be using the IUS, IUD, contraceptive implant, or contraceptive injection for at least 3 months prior to Visit 1 without clinically significant complications in the opinion of the Investigator.
  • Vaginal forms of contraception such as contraceptive foams/gels, diaphragms, penile or vaginal condoms, contraceptive vaginal rings, and are not considered acceptable methods of birth control in this study.
  • While latex and polyisoprene condoms are not an acceptable form of contraception, they may be used for the prevention of sexually transmitted infections.
  • Patient has a body mass index (BMI) from 18 to 35 kg/m2, inclusive.
  • Patient has had a Pap smear performed within three years prior to Visit 1 and can provide documentation indicating normal test results (based on current guidelines as published by the U.S. Preventive Services Task Force).
  • If the patient cannot provide documentation, a Pap smear will be performed at Visit 1.
  • Patients with abnormal findings will be excluded from study participation and be referred for follow-up medical care as appropriate.
  • Patient is medically healthy with no clinically significant medical history, physical examination, gynecological history and examination, laboratory profiles (e.g., hematology, urinalysis), vital signs (e.g., uncontrolled hypertension), or ECGs, as deemed by the Investigator.
  • Patients who have clinically significant ECG abnormalities at Visit 1 as confirmed by the Investigator will be excluded.
  • Patients with controlled, treated hypertension (<140/90 mmHg) on up to two medications (excluding alpha blockers and nitrates) with a stable dose for the past 6 months will be considered eligible.
  • Patients with controlled, treated thyroid disease on a stable medication and dose for the past 6 months will be considered eligible. TSH must be within normal range (confirmed by laboratory test).
  • The participant must agree to not use vaginal hormone therapy (e.g., vaginal estrogen, intravaginal prasterone), vaginal or vulvar lubricants, spermicides, creams or gels, contraceptive foams or vaginal douche products throughout the study period.
  • Women who self-report abnormal physiological vaginal discharge will be excluded until abnormal physiological discharge resolves.
  • Patients using systemic (transdermal or oral) therapy must be on a stable dose for at least 6 months prior to Visit 1.
  • Patient must have a total score on the FSDS-DAO >18 through visit 4.

Who cannot join

  • Patient is nursing or pregnant (based on positive serum pregnancy test), wishes to become pregnant or begin nursing during the study period or was pregnant or nursing within 6 months prior to Visit 1.
  • Patient has more than one sexual partner.
  • Patient is postmenopausal (surgically induced or natural) meeting any of the following criteria:
  • Bilateral oophorectomy.
  • 12 months of spontaneous amenorrhea
  • 6 months of spontaneous amenorrhea with serum FSH levels >40mIU/mL (except for those women on hormone replacement therapy)
Show all 49Show fewer
  • Patient has any disorder or a history of any disorder that may prevent the successful completion of the study in the opinion of the Investigator.
  • Patient has a significant cardiovascular, hepatic, metabolic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, genitourinary, or other unstable medical condition that would contraindicate administration of study medication, interfere with study evaluation, limit study participation, or confound the interpretation of study results in the opinion of the Investigator.
  • Patient has a history of unresolved sexual trauma or abuse that is contributing to any sexual dysfunction problem (desire, arousal, orgasm, etc.) as determined by the clinical interview.
  • Patient with any history of active peptic ulcers or clinically significant bleeding disorders.
  • Patient with a history of clitoral priapism or conditions which may predispose them to clitoral priapism (such as sickle cell anemia, multiple myeloma, or leukemia).
  • Patients with a history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to Visit 1; patients with resting hypotension (BP <90/50 mmHg); or any history of coronary disease causing angina; or congestive heart failure requiring medical intervention; patients with underlying conditions which can be particularly sensitive to the actions of vasodilators including patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and patients with impaired autonomic control of blood pressure, or for those for which sexual activity is inadvisable due to their underlying cardiovascular status.
  • Patient with a history of hearing loss (unless born completely deaf).
  • Patient has retinitis pigmentosa, even if the patient feels clinically well at the time of Visit 1. Patients with retinitis pigmentosa will be identified by specifically asking whether they have the condition, if there are visual signs and symptoms of the condition (including questioning patients as to whether they have difficulty seeing at night or in low light, and if they have any visual field deficits that indicate a loss of peripheral or central vision), or if there is a family history.
  • Patient has a history of orthostatic hypotension or orthostatic hypotension which is present at Visit 1, defined as a drop in systolic blood pressure ≥ 20 mm Hg, a drop in diastolic blood pressure ≥ 10 mm Hg, an increase in pulse by 20 beats per minute or experiencing lightheadedness or dizziness at 1 or 3 minutes after the change in position from supine to standing.
  • Patient has a primary complaint of anorgasmia, vaginismus, low desire, or any other primary sexual complaint aside from problems with genital arousal, as determined by the clinical interview.
  • Patient has untreated dyspareunia, vulvovaginal infection or inflammation, inflammatory disorders of the vulva or vagina, vestibulodynia, clitorodynia, or symptomatic vulvovaginal atrophy (defined as women having ≤5% of superficial cells on vaginal smear at baseline,
  • Patient has undergone major pelvic or abdominal surgery that may have caused nerve damage, including, vulvectomy, colostomy, cystostomy, hysterectomy and bladder neck suspension.
  • Patients with comorbid conditions that may cause underlying neurological impairment (i.e., Type 1 or Type 2 diabetes, metabolic syndrome, stroke, myasthenia gravis, multiple sclerosis or spinal cord damage) will be excluded.
  • Patients who are symptomatic of peripheral neuropathy will be excluded.
  • Patients with pelvic nerve damage secondary to trauma will be excluded.
  • With the exception of anxiety and depression, patient has any current and/or previously reported diagnoses of DSM-IV-TR axis I disorders (e.g., schizophrenia, bipolar disorder) including delirium, dementia and amnestic disorders.
  • Patients diagnosed with anxiety or depression must be controlled, as determined by the Investigator, and if on a medication (i.e., SSRIs, SNRIs, buspirone, bupropion, and benzodiazepines), on a stable dose for at least the past 6 months.
  • Patients must have a total score <10 indicating mild depression on the Patient Health Questionnaire-8 (PHQ-8, Appendix G) (a screening and assessment instrument for depression).
  • Patients must have a total score <6 indicating mild anxiety on the Generalized Anxiety Disorder (GAD-7, Appendix H) (a screening and assessment instrument for anxiety).
  • Patients who have any history of anti-psychotic therapy within the last year will be excluded.
  • Patients that have a history of gynecological cancer or are under active treatment (or recently completed treatment within the last 6 months) for any cancer which in the Investigator's judgement would interfere with the patient's ability to successfully complete the study will be excluded.
  • Patients who have been previously treated for dysplasia (precancerous changes) may be included as long as the patient received localized treatment (e.g., cryosurgery or laser).
  • Patients with a history of radiation to the pelvis will be excluded.
  • Patient has any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article in the opinion of the Investigator.
  • Patient self-reports a history of substance abuse within two years prior to Visit 1 or exhibits signs of current substance abuse based on Investigator judgement.
  • Patient self-reports a history of alcohol abuse in the two years prior to Visit 1 or exhibits signs of current alcohol abuse based on Investigator judgement.
  • Patient has a history of non-arteritic ischemic optic neuropathy (NAION) or any underlying NAION risk factors.
  • Patient whose sexual function was affected (enhanced or worsened) by any medication within 28 days before Visit 1 and at any time prior to the No Drug Run-in Period of the study.
  • Patient is currently receiving treatment or has received treatment within 1 month (28 days) prior to Visit 1 of any of the following medications: guanylate cyclase stimulators (e.g., Riociguat), clonidine, strong CYP3A4 inhibitors, nitric oxide donors, such as organic nitrates or organic nitrites, and alpha blockers.
  • Patients who are currently receiving treatment or have received treatment in the past 3 months for FSAD symptoms, pharmacologic (e.g., PDE5 inhibitors in any form except Sildenafil Cream, 3.6% or other experimental therapies used to enhance the arousal response) or non-pharmacologic treatment (e.g., sex therapy), will also be excluded.
  • Patient has positive findings from the urine drug screen (e.g., amphetamines, barbiturates, cocaine, methadone, and opiates). Patients who test positive for amphetamines but are being treated for ADHD with a confirmed legal prescription will be allowed to participate.
  • Patient has positive findings for sexually transmitted infection (gonorrhea, trichomoniasis, chlamydia), and human immunodeficiency virus (HIV) antibodies.
  • Patient reports having an outbreak (blisters, warts, or vesicles) due to any of the following sexually transmitted diseases: genital herpes or HPV at any time point in the past three months.
  • Patient has participated in any clinical research study evaluating another investigational drug or therapy within 30 days before Visit 1 (or 6 half-lives of the investigational agent, whichever is longer) and agrees not to participate in another clinical research study throughout the duration of the study.
  • Patient has any clinically significant abnormal findings on vulvar-vaginal examination performed during the physical and gynecological exams at Visit 1 (e.g., genital skin breaks, irritation, dermatoses, or lesions).
  • Patient currently has moderate to severe current vaginitis, a vaginal infection including bacterial vaginosis, a yeast infection or the presence of yeast based on the Nucleic Acid Amplification (NAAT).
  • If the patient has a vaginal infection or a positive test for yeast during the screening visit, they may be treated, and the screening visit rescheduled.
  • If the patient develops a vaginal infection following enrollment into the study, study drug will be withheld, and the patient will be treated for the infection. If the infection cannot be resolved within two weeks the patient will be withdrawn from the study. Treatment of vaginal infections will be allowed twice following enrollment. If the patient develops a third vaginal infection they will be withdrawn from the study.
  • Patient has a pelvic or urinary tract infection.
  • If the patient has a urinary tract infection during the screening visit, they may be treated, and the screening visit rescheduled.
  • If the patient develops a urinary tract infection following enrollment into the study, study drug will be withheld, and the patient will be treated for the infection. If the infection cannot be resolved within two weeks the patient will be withdrawn from the study. Treatment of urinary tract infections will be allowed twice following enrollment. If the patient develops a third urinary tract infection they will be withdrawn from the study.
  • Patient self-reports a known hypersensitivity or adverse reaction to any ingredients in the Investigational Product (IP).
  • The patient is an immediate family member, a study site employee, or is in a dependent relationship with a study site employee or anyone who is involved in the conduct of the study (e.g., spouse, parent, child, sibling) or may consent under duress.

Trial locations and contacts

51 sites in 1 country.

Kathy Cornell contact

774-473-4414

kcornell@strategicscience.com

51 sites in 1 country

United States51 sites, 51 recruiting

  • AGILE Clinical Research Trials

    Atlanta, Georgia, 30342

    Recruiting

  • South Florida Medical Research

    Aventura, Florida, 33180

    Recruiting

  • Boston Clinical Trials

    Boston, Massachusetts, 02131

    Recruiting

  • ClinSearch

    Chattanooga, Tennessee, 37421

    Recruiting

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640

    Recruiting

  • Velocity Clinical Research - Cleveland (Rapid Medical Research)

    Cleveland, Ohio, 44122

    Recruiting

  • Aventiv Research, inc.

    Columbus, Ohio, 43214

    Recruiting

  • Southern Institute for Women's Sexual Health

    Covington, Louisiana, 70433

    Recruiting

  • iResearch Atlanta

    Decatur, Georgia, 30030

    Recruiting

  • Downtown Women's Healthcare

    Denver, Colorado, 80209

    Recruiting

  • AMR Fort Myers

    Fort Myers, Florida, 33912

    Recruiting

  • Collaborative Neuroscience Network

    Garden Grove, California, 92845

    Recruiting

  • TMC Life Research

    Houston, Texas, 77054

    Recruiting

  • Rosemark Women Care Specialists

    Idaho Falls, Idaho, 83404

    Recruiting

  • Clinical Neuroscience Solutions-Orlando

    Jacksonville, Florida, 32256

    Recruiting

  • Essential Women's Health Associates

    Las Vegas, Nevada, 89113

    Recruiting

  • Office of Doctor Rex G. Mabey Junior

    Las Vegas, Nevada, 89128

    Recruiting

  • Women's Health Research Center

    Lawrenceville, New Jersey, 086489

    Recruiting

  • Maximos Obstetrics and Gynecology

    League City, Texas, 77573

    Recruiting

  • Praetorian Pharmaceutical Research

    Marrero, Louisiana, 70072

    Recruiting

  • University Hospitals Landerbrook

    Mayfield Heights, Ohio, 44124

    Recruiting

  • Clinical Neuroscience Solutions - Memphis

    Memphis, Tennessee, 38119

    Recruiting

  • Medical Research Center of Memphis

    Memphis, Tennessee, 38120

    Recruiting

  • New Age Medical Research Corporation

    Miami, Florida, 33186

    Recruiting

  • New Jersey Urology - Bloomfield

    Millburn, New Jersey, 07041

    Recruiting

  • Coastal Clinical Research

    Mobile, Alabama, 36608

    Recruiting

  • The Center for Specialized Women's Health

    Morristown, New Jersey, 07960

    Recruiting

  • Urology Associates - Nashville

    Nashville, Tennessee, 37209

    Recruiting

  • Coastal Connecticut Research, LLC

    New London, Connecticut, 06320

    Recruiting

  • Suncoast Clinical Research - Pasco County

    New Port Richey, Florida, 34652

    Recruiting

  • Health Research of Hampton Roads, Inc.

    Newport News, Virginia, 23606

    Recruiting

  • Tidewater Clinical Research

    Norfolk, Virginia, 23502

    Recruiting

  • Coastal Carolina Research Center

    North Charleston, South Carolina, 29405

    Recruiting

  • Healthcare Clinical Data, Inc.

    North Miami, Florida, 33161

    Recruiting

  • Rivus Wellness & Research Institute

    Oklahoma City, Oklahoma, 73112

    Recruiting

  • Quality Clinical Research

    Omaha, Nebraska, 68114

    Recruiting

  • Omaha OB GYN Associates, P.C.

    Omaha, Nebraska, 68130

    Recruiting

  • NRC Research Institute

    Orange, California, 92868

    Recruiting

  • CNS Healthcare

    Orlando, Florida, 32801

    Recruiting

  • Precision Clinical Trials-Arizona

    Phoenix, Arizona, 85032

    Recruiting

  • Suffolk Obstetrics and Gynecology

    Port Jefferson, New York, 11777

    Recruiting

  • Women's OB-GYN, P.C. dba Saginaw Valley Medical

    Saginaw, Michigan, 48604

    Recruiting

  • Clinical Trials of Texas

    San Antonio, Texas, 78229

    Recruiting

  • Medical Center for Clinical Research - San Diego

    San Diego, California, 92108

    Recruiting

  • Seattle Women's Health Research - Gynecology

    Seattle, Washington, 98105

    Recruiting

  • Schuster Medical Research Institute

    Sherman Oaks, California, 91403

    Recruiting

  • Visions Clinical Research -Tucson

    Tucson, Arizona, 85712

    Recruiting

  • Velocity Clinical Research, Providence

    Warwick, Rhode Island, 02886

    Recruiting

  • Intimmedicine Specialists

    Washington D.C., District of Columbia, 20036

    Recruiting

  • Comprehensive Clinical Research, LLC

    West Palm Beach, Florida, 33409

    Recruiting

  • Cypress Medical Research Center

    Wichita, Kansas, 67226

    Recruiting

Other trials in United States

About this study

Official title: A Phase 2b, Multi-Center, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sildenafil Cream, 3.6% in Premenopausal Patients With Female Sexual Arousal Disorder (FSAD)

This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.

Being tested
Sildenafil, Placebo
Keywords
Sexual Disorder, Arousal Disorder, FSAD
Medical subject headings
Sexual Dysfunction, Physiological

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SildenafilDrug

    Patients will apply 2-gram applications up to 9 times per month.

  • PlaceboDrug

    Patients will apply 2-gram applications up to 9 times per month

Study groups in NCT04948151
Study groupRoleWhat they receive
Sildenafil Cream, 3.6%ExperimentalNot described
Receives: Drug: Sildenafil
Placebo CreamPlacebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SFQ28 (AS) - 28 Day Recall

    Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the Arousal-Sensation Domain of the SFQ28.

    Measured: SFQ28 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.

  2. FSDS-DAO (Q14) - 28 Day Recall

    Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the score for feeling concerned by difficulties with sexual arousal - Item #14 only of the FSDS-DAO.

    Measured: Q14 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.

Secondary outcomes (1)

  1. Arousal Diary (SSE)

    Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the number of Satisfactory Sexual Events, question #11 in teh ARousal Diary.

    Measured: measured by daily prompt within 24hrs after each sexual event during the Single-Blind Placebo Run-In compared to the last 4 weeks of the Double-Blind Dosing Period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jul 2021
  2. Study start28 Jun 2021 (estimated)
  3. Primary completion15 Dec 2021 (estimated)
  4. Study completion15 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
440 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04948151
Sponsor's protocol ID
SST-6006-013
Acronym
RESPOND
Status last verified
Jun 2021
First submitted
24 Jun 2021
Last updated
1 Jul 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Johnson I, Thurman AR, Cornell KA, Symonds T, Hatheway J, Friend DR, Goldstein A. Comparisons and correlations of 1-month recall vs 24-hour recall in patient-reported outcomes of an exploratory, phase 2b, randomized, double-blind, placebo-controlled clinical trial of sildenafil cream, 3.6% for the treatment of female sexual arousal disorder. J Sex Med. 2024 Sep 3;21(9):787-792. doi: 10.1093/jsxmed/qdae086.

    PubMed 39059373

  • Johnson I, Thurman AR, Cornell KA, Hatheway J, Dart C, Brainard CP, Friend DR, Goldstein A. Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder: A Randomized Controlled Trial. Obstet Gynecol. 2024 Aug 1;144(2):144-152. doi: 10.1097/AOG.0000000000005648. Epub 2024 Jun 18.

    PubMed 38889431

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Sildenafil in people with Female Sexual Arousal Disorder, run by Strategic Science & Technologies, LLC at 51 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 49 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 51 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kathy Cornell (774-473-4414, kcornell@strategicscience.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SFQ28 (AS) - 28 Day Recall (time frame: SFQ28 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04948151, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in